MannKind Corp
$ 5.54
-0.54%
24 Feb - close price
- Market Cap 1,556,846,000 USD
- Current Price $ 5.54
- High / Low $ 5.74 / 5.50
- Stock P/E 50.70
- Book Value -0.14
- EPS 0.10
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE N/A %
- 52 Week High 6.51
- 52 Week Low 3.38
About
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Analyst Target Price
$9.44
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-09 | 2023-02-22 |
| Reported EPS | 0.07 | 0.05 | 0.04 | 0.0255 | 0.05 | -0.01 | 0.04 | 0.0043 | 0.01 | -0.02 | -0.04 | -0.07 |
| Estimated EPS | 0.02 | 0.05 | 0.06 | 0.03 | 0.03 | 0.01 | 0.03 | 0.01 | -0.02 | -0.04 | -0.05 | -0.06 |
| Surprise | 0.05 | 0 | -0.02 | -0.0045 | 0.02 | -0.02 | 0.01 | -0.0057 | 0.03 | 0.02 | 0.01 | -0.01 |
| Surprise Percentage | 250% | 0% | -33.3333% | -15% | 66.6667% | -200% | 33.3333% | -57% | 150% | 50% | 20% | -16.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNKD
2026-02-19 23:40:00
MannKind Corporation announced that CEO Michael Castagna will present a business update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET. A webcast of the presentation will be available on the company's investor relations website, with recorded versions accessible for about 90 days afterward. MannKind is a biopharmaceutical company focused on chronic disease care for conditions like diabetes and pulmonary hypertension.
2026-02-19 13:57:24
MannKind Corporation announced that CEO Michael Castagna is scheduled to present and provide business updates at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 11:20 a.m. ET. A webcast of the presentation will be available on the company's investor relations website, with recorded versions also accessible for approximately 90 days. MannKind is a biopharmaceutical company focused on transforming chronic disease care, particularly in cardiometabolic and orphan lung diseases.
2026-02-19 02:57:24
MannKind (NASDAQ: MNKD) is scheduled to release its Q4 2025 earnings before the market opens on Wednesday, February 25th, with analysts forecasting a loss of ($0.01) per share. The biopharmaceutical company, which specializes in inhaled therapeutic products like Afrezza for diabetes, currently has a "Moderate Buy" consensus rating and a target price of $10.06 from Wall Street analysts. Recent insider selling, including by CEO Michael Castagna, totals $1.55 million over the last 90 days, while institutional investors have increased their holdings.
2026-02-18 03:27:33
MannKind Corporation announced it will release its fourth-quarter and full-year 2025 financial results before market open on Thursday, February 26, 2026. The biopharmaceutical company will also host a webcast at 9:00 a.m. Eastern Time to discuss the results and provide a business update, with a replay available on their investor relations website. MannKind specializes in innovative, patient-centric solutions for cardiometabolic and orphan lung diseases.
2026-02-15 15:27:20
MannKind has initiated enrollment for its pivotal INHALE-1ST trial of Afrezza inhaled insulin in pediatric patients, specifically for newly diagnosed type 1 diabetes in children and adolescents. This trial, along with a pending FDA review for pediatric label expansion, could make Afrezza the first needle-free insulin option for young patients in the U.S. Investors are closely watching clinical outcomes and the FDA's decision, which are expected to significantly influence Afrezza's market potential and adoption in youth diabetes care.
2026-02-09 12:29:41
MannKind Corporation (MNKD) has commenced enrollment for INHALE-1ST, a pivotal clinical trial evaluating its Afrezza Inhalation Powder for early intervention in pediatric type 1 diabetes. Despite strong revenue growth and profitability metrics, as well as solid liquidity, the company faces concerns regarding insider selling and a low Altman Z-Score indicative of financial distress risks. Investors are advised to consider the mixed valuation metrics and sector-specific risks, alongside potential catalysts from clinical trial results.
